Etzer Darout
Stock Analyst at BMO Capital
(2.22)
# 2,560
Out of 4,778 analysts
108
Total ratings
34.57%
Success rate
-0.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Maintains: Outperform | $82 → $20 | $8.07 | +147.83% | 4 | Mar 12, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Outperform | $62 → $72 | $50.02 | +43.94% | 2 | Mar 11, 2025 | |
| BNTX BioNTech SE | Maintains: Outperform | $130 → $143 | $97.28 | +47.01% | 4 | Mar 11, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $22 → $3 | $2.02 | +48.51% | 3 | Feb 11, 2025 | |
| IGMS IGM Biosciences | Downgrades: Market Perform | $21 → $2 | $1.21 | +65.29% | 2 | Jan 10, 2025 | |
| EXEL Exelixis | Downgrades: Market Perform | $36 → $40 | $36.86 | +8.53% | 3 | Dec 20, 2024 | |
| TRML Tourmaline Bio | Initiates: Outperform | $50 | $16.80 | +197.62% | 1 | Dec 6, 2024 | |
| NRIX Nurix Therapeutics | Initiates: Outperform | $35 | $12.25 | +185.71% | 1 | Dec 6, 2024 | |
| KYMR Kymera Therapeutics | Initiates: Market Perform | $55 | $30.78 | +78.69% | 1 | Dec 6, 2024 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $63 | $4.82 | +1,207.08% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $3.40 | +694.66% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $73.36 | +82.66% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 → $34 | $11.39 | +198.51% | 5 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $19.76 | +142.98% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $109.57 | +9.52% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $38 | $32.43 | +17.18% | 3 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 → $26 | $3.17 | +720.19% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $25 | $4.88 | +412.30% | 6 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $5 | $1.74 | +187.36% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $2.02 | +892.56% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $91 | $45.68 | +99.23% | 5 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $0.88 | +580.89% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3.25 → $3.59 | $0.60 | +498.33% | 10 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $72.34 | +13.35% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.94 | +308.16% | 2 | Sep 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $3.91 | +385.93% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $273.09 | -37.75% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $84 | $5.52 | +1,423.12% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $54 | $42.90 | +25.87% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $46.23 | -17.80% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $1.61 | +3,139.88% | 1 | Mar 28, 2018 |
Arvinas
Mar 12, 2025
Maintains: Outperform
Price Target: $82 → $20
Current: $8.07
Upside: +147.83%
Protagonist Therapeutics
Mar 11, 2025
Reiterates: Outperform
Price Target: $62 → $72
Current: $50.02
Upside: +43.94%
BioNTech SE
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $97.28
Upside: +47.01%
Q32 Bio
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $2.02
Upside: +48.51%
IGM Biosciences
Jan 10, 2025
Downgrades: Market Perform
Price Target: $21 → $2
Current: $1.21
Upside: +65.29%
Exelixis
Dec 20, 2024
Downgrades: Market Perform
Price Target: $36 → $40
Current: $36.86
Upside: +8.53%
Tourmaline Bio
Dec 6, 2024
Initiates: Outperform
Price Target: $50
Current: $16.80
Upside: +197.62%
Nurix Therapeutics
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $12.25
Upside: +185.71%
Kymera Therapeutics
Dec 6, 2024
Initiates: Market Perform
Price Target: $55
Current: $30.78
Upside: +78.69%
Jasper Therapeutics
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $4.82
Upside: +1,207.08%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $3.40
Upside: +694.66%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $73.36
Upside: +82.66%
Nov 8, 2024
Reiterates: Outperform
Price Target: $32 → $34
Current: $11.39
Upside: +198.51%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $19.76
Upside: +142.98%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $109.57
Upside: +9.52%
Oct 11, 2024
Maintains: Outperform
Price Target: $34 → $38
Current: $32.43
Upside: +17.18%
Sep 16, 2024
Reiterates: Outperform
Price Target: $19 → $26
Current: $3.17
Upside: +720.19%
Aug 13, 2024
Maintains: Outperform
Price Target: $26 → $25
Current: $4.88
Upside: +412.30%
Aug 7, 2024
Maintains: Market Perform
Price Target: $8 → $5
Current: $1.74
Upside: +187.36%
Aug 6, 2024
Reiterates: Outperform
Price Target: $20
Current: $2.02
Upside: +892.56%
Jun 4, 2024
Maintains: Outperform
Price Target: $84 → $91
Current: $45.68
Upside: +99.23%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $0.88
Upside: +580.89%
May 9, 2024
Maintains: Market Perform
Price Target: $3.25 → $3.59
Current: $0.60
Upside: +498.33%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $72.34
Upside: +13.35%
Sep 1, 2023
Reiterates: Buy
Price Target: $12
Current: $2.94
Upside: +308.16%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $3.91
Upside: +385.93%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $273.09
Upside: -37.75%
Jul 12, 2021
Initiates: Buy
Price Target: $84
Current: $5.52
Upside: +1,423.12%
Feb 26, 2021
Initiates: Buy
Price Target: $54
Current: $42.90
Upside: +25.87%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $46.23
Upside: -17.80%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $1.61
Upside: +3,139.88%